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A large body of evidence from recent studies has shown that 
tocotrienols, the vitamin E molecules with an unsaturated farnesyl side 
chain, have potential in the prevention and/or treatment of cancer, 
metabolic syndrome, obesity, diabetes, osteoporosis, and neuro-
degeneration [1]. These activities of tocotrienols may converge on the 
emerging finding that tocotrienols suppress the activation of nuclear 
factor kappa B (NFκB), a major mediator in chronic inflammation 
that is gaining recognition as one of the main mechanisms underlying 
these chronic diseases. Tocotrienol-mediated inhibition of NFκB 
DNA binding activity or suppression of tumor necrosis factor α- and 
lipopolysaccharide-induced NFκB expression has been demonstrated 
in human breast cancer cells [2,3], colon carcinoma cells [4], malignant 
melanoma cells [5], pancreatic cancer cells [6], gastric cancer cells [7], 
metastatic oral cancer cells [8], adipocytes [9], and macrophages [10]. 
Moreover, the in vitro NFκB-suppressive activity of tocotrienols was 
borne out in gastric cancer [7] and pancreatic cancer [11] in nude mice. 
Readers are referred to recent reviews [12-14] for more details on the 
anti-inflammatory activity of tocotrienols.
A closer examination of the NFκB-suppressive activity of 
tocotrienols revealed a more fundamental biological activity of 
tocotrienols; NFκB suppression may be a secondary effect of tocotrienol-
mediated down-regulation of another biochemical pathway that is 
ubiquitous in virtually all eukaryotic cells: the mevalonate pathway [15]. 
The mevalonate pathway operating in sterologenic tissues provides – in 
addition to cholesterol that is an essential component of cell membrane 
and a precursor to vitamin D, bile acids and steroid hormones-essential 
intermediates including farnesyl- and geranylgeranyl- pyrophosphates 
for the post-translational prenylation of growth-related proteins such 
as Ras and nuclear lamins and N-linked glycosylation of insulin-like 
growth factor receptor I. Most importantly, prenylated Ras activates 
NFκB [16]. 
The rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-
3-methylglutaryl coenzyme A (HMG CoA) reductase, is under a 
multivalent regulation consisting of sterol-mediated transcriptional 
feedback inhibition and a non-sterol-mediated post-transcriptional 
down-regulation. Tocotrienols suppress HMG CoA reductase at both 
transcriptional and post-transcriptional levels [17] and consequently, 
deplete the pool of prenyl pyrophosphates required for the prenylation 
of Ras and inactivate NFκB. Ahn et al. showed that tocotrienol-mediated 
ablation of NFκB activity was reversed by supplemental mevalonate, 
the product of the reaction catalyzed by HMG CoA reductase [15], 
establishing mevalonate deprivation as the primary cause for NFκB 
inactivation.
Tocotrienols may represent a broad class of isoprenoids 
encompassing approximately 23,000 mevalonate-derived end-products 
of plant secondary metabolism. Isoprenoids can be classified based on 
the number of isoprene units they contain, e.g. monoterpene (2x), 
sesquiterpene (3x), diterpene (4x), triterpene (6x) and polyterpene 
(Nx) [18]. In addition to these “pure” isoprenoids, the “mixed” 
isoprenoids including the tocotrienols have non-mevalonate-derived 
moieties. Assorted isoprenoids have a wide spectrum of functions in 
the plant kingdom, ranging from growth regulation to insect attraction, 
pollination assistance, and pest resistance. Fruits, vegetables and grains 
are the main sources of dietary isoprenoids.
The HMG CoA reductase-suppressive activity is extensively 
observed among isoprenoids [19]. It is therefore no coincidence that 
a number of isoprenoids under investigation also suppress NFκB 
activity. The monoterpene limonene inhibited NFκB activation in 
human HL60 clone 15 leukemia cells [20] while an oxidative product 
of limonene, perillyl alcohol, suppressed NFκB in B-lymphoma cells 
[21]. A third monoterpene, geraniol, suppressed 12-O-tetradecanoyl 
phorbol-13-acetate (TPA)-induced inflammatory responses and up-
regulation of NFκB and COX-2 in mice [22]. A sesquiterpene β-ionone 
inhibited tumor necrosis factor–related apoptosis-inducing ligand 
(TRAIL)-induced NFκB activation in human HepB3 and HepG2 
hepatocellular carcinoma cells [23]. Various sesquiterpene lactones 
blocked NFκB activity [24]. Diterpene coronarin D suppressed NFκB 
activation in human KBM-5 chronic myeloid leukemia and A293 
embryonic kidney carcinoma cells [25]. Garcinol, a polyisoprenylated 
benzophenone, inhibited the activation of NFκB in human BxPC-3 and 
Panc-1 pancreatic cancer cells [26] and squamous cell carcinoma of 
the head and neck [27]. Lastly, a triterpene lupeol suppressed TPA-
induced activation of NFκB in CD-1 mice [28]. 
More support for the mevalonate-inflammation connection is 
drawn from studies with the statins, competitive inhibitors of HMG 
CoA reductase, and protein prenyl transferase inhibitors showing their 
parallel impacts on NFκB. Simvastatin inhibited NFκB activation in 
human COLO 205 colon cancer cells [29], squamous cell carcinoma 
SCC4 cells and KBM-5 cells [30]. Statins also suppressed the tumor 
necrosis factor α- [31] and receptor activator of NFκB ligand (RANKL) 
- [32] induced activation of NFκB in RAW 264.7 macrophages. 
C-reactive protein-induced NFκB activation was inhibited by 
simvastatin in human umbilical vein endothelial cells; reminiscent of 
the findings by Ahn et al. with tocotrienols [15], mevalonate attenuated 
the simvastatin effect on NFκB [33]. Consequent to Ras inactivation 
[34], farnesyl transferase inhibitors FTI-276 and SCH 66336 suppressed 
NFκB activation in rheumatoid arthritis synovial fibroblasts [35], 
human Jurkat T-cell lymphoma cells, H1299 lung adenocarcinoma 
cells, MCF-7 breast adenocarcinoma cells, and A293 embryonic kidney 
cells [34]. 
By depleting mevalonate and consequently suppressing NFκB 
activity, isoprenoids and most prominently tocotrienols may deliver 
a “one-two punch” to inflammation. The omnipresence of the 
mevalonate pathway and the critical role of inflammation in chronic 
disorders suggest that dietary isoprenoids warrant further investigation 
for their potential roles in the prevention and managing of chronic 
diseases. 
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